# A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

> **NCT00335270** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 100 (—)

## Conditions studied

- HIV

## Interventions

- **DRUG:** fos-amprenavir calcium, ritonavir
- **DRUG:** abacavir/lamivudine as Epzicom

## Key facts

- **NCT ID:** NCT00335270
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 100 (—)
- **Last updated:** 2013-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335270, "A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00335270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*